An Open Multi-center Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCTB39-1 in Adult Patients With Advanced Malignant Solid Tumours
Latest Information Update: 11 Jul 2025
At a glance
- Drugs SCTB 39-1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sinocelltech
Most Recent Events
- 11 Jul 2025 New trial record